We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Leica Microsystems Signs Distribution Agreement with French Company

By Labmedica staff writers
Posted on 10 Apr 2007
Leica Microsystems (Wetzlar, Germany) and Mauna Kea Technologies (MKT; Paris, France) signed an exclusive distribution agreement for the German high-tech optics company to market the innovative system developed by Mauna Kea Technologies. More...
The two companies are collaborating to improve research and to discover therapies against serious diseases worldwide

Leica Microsystems thus enlarges its product portfolio to include an endoscopic confocal microscope for in-vivo research applications. The agreement covers Europe, North America, and Japan. Cellvizio, as the system is called, will be adopted marketed as Leica FCM1000 (fiber-confocal microscope).

Leica FCM1000 with Cellvizio technology is a fiberoptic confocal fluorescence microscope for dynamic in vivo imaging. Its movable, minimally invasive probe allows it to be introduced non-destructively into the insides of living animals, producing video image sequences at a rate of 12 frames per second. There is a strongly increasing demand for in vivo microscopy, to complement classical in-vitro studies, so this new product is the ideal addition to our portfolio of state of the art confocal microscopes, explained Leica's executive vice president of sales and marketing, David Martyr.

This small animal imaging system is used in pre-clinical research in academic research institutions and biotechnologic and pharmaceutic companies. Primarily conducted on rodents, these experiments play a key role in neurologic research in deep brain and peripheral nerves imaging, especially in the research of degenerative diseases such as Alzheimer's and Parkinson's, and in cancer, cardiovascular and stem cell research, gene delivery, and tissue engineering.

Sacha Loiseau, president of Mauna Kea Technologies, explained, We are extremely proud of this major agreement between Mauna Kea Technologies and the prestigious company Leica Microsystems. It tangibly recognizes MKT's innovative R&D and leadership in non-invasive cellular and molecular imaging solutions. This achievement is the result of MKT's effort to gather the best team of scientists and engineers to develop new imaging technologies that are perfectly adapted to customer needs. The commercial agreement with Leica Microsystems will make it possible for thousands of researchers worldwide to benefit from the breakthroughs offered by Leica FCM1000 with Cellvizio technology.


Related Links:
Leica Microsystems
Mauna Kea Technologies

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.